Sitemap

Medicine Questions

Report an Adverse Event

Investors

Contact

Our Company

Mission and Core Values

Leadership

Governance and Committees

U.S. Public Policy Engagement

Political Contributions Archives

Policies and Disclosures

Supplier Information

Supplier Enablement Resources

Supplier Inclusion

U.S. Locations

Our Purpose

Partnerships and Community

COMPASS Initiative

HIV Age Positively

Toward Health Equity for Black People Impacted by TNBC

Toward Health Equity Oncology Grant

Corporate Giving

Funding Requests

Zeroing In: Ending the HIV Epidemic

Gilead Foundation

Creating Possible Fund

Inclusion and Diversity

Environmental, Social, Governance (ESG)

U.N. Global Compact

U.N. Sustainable Development Goals

Sustainability

Our Business Is Sustainable

Advancing Global Health

HCV Elimination

Medication Access

U.S. Patient Access

Disaster Product Replacement

Authorized Distributors

Science & Medicine

Our Therapeutic Areas

Medicines

Pipeline

Research

Research Scholars Program

Compassionate Use

Investigator-Sponsored Research

Clinical Trials

News and Press

Events

Stories

Newsroom

Media Inquiries

Company Statements

Gilead Statement on Favorable Verdict in HIV PrEP Patents Litigation

Gilead Remains Steadfast in Support for Hepatitis C Elimination Efforts

Gilead Sciences Statement on Sustaining Access to AmBisome® in Low- and Middle-Income Countries

Christi Shaw to Depart Gilead and Kite Leadership End of Q1

Gilead Sciences Commends Convictions in Counterfeiting Scheme Pledges Continued Commitment to Protect Patients

Gilead Enables Easier Veklury® (Remdesivir) Access Through Retail and Specialty Pharmacies for Long-Term Care and Skilled Nursing Facilities

Gilead Receives Complete Response Letter from U.S. FDA for Bulevirtide for the Treatment of Adults with Hepatitis Delta Virus

Gilead Continues Efforts to Halt the Distribution of Counterfeit HIV Medications and Protect Patient Safety

Veklury® (Remdesivir) Demonstrates Continued In Vitro Antiviral Activity Against Omicron Subvariants, Including BA.4 and BA.5

Sacituzumab Govitecan-Hziy Trodelvy Elevated to Category 1 Preferred Recommendation in Second-Line Metastatic Triple-Negative Breast Cancer

Gilead Sciences Statement on FDA Acceptance of New Drug Application for Investigational Lenacapavir

Gilead Statement on U.S. Supreme Court Overturning Roe v. Wade

All Magrolimab Studies Re-Opening for Patient Enrollment in the U.S.

Gilead Statement on WHO Recommendation of Veklury® (Remdesivir) and Acceleration of Prequalification Submission

Gilead Implements Contract Pharmacy Integrity Initiative for Branded Hepatitis C Products

Gilead to Expand Footprint in Oceanside

Gilead Expands Availability of Veklury® (remdesivir) to Non-Hospital Outpatient Facilities

Gilead Announces Global Resolution of Bictegravir Patent Dispute with ViiV Healthcare

Gilead Announces Actions to Remove Counterfeit HIV Medications from US Supply Chain

Gilead Statement on Zydelig® U.S. Indication for Follicular Lymphoma and Small Lymphocytic Leukemia

Veklury® (Remdesivir) Receives Positive CHMP Opinion for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression

Gilead Issues a Voluntary Nationwide Recall of Two Lots of Veklury® (Remdesivir) Due to Presence of Glass Particulates

Gilead Statement on Veklury® (Remdesivir) and the SARS-CoV-2 Omicron Variant

Gilead and Merck Announce Temporary Pause in Enrollment for Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Islatravir and Investigational Lenacapavir

Gilead Announces Decision Not to Pursue Marketing Authorization for Descovy® for Pre-Exposure Prophylaxis in the European Union

Gilead Statement on New NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Recommendation for Sacituzumab Govitecan-Hziy (Trodelvy®) in Second-Line and Later Metastatic Triple-Negative Breast Cancer

Gilead Sciences Statement on Requiring Vaccination Against COVID-19 for Employees

Gilead Warns of Counterfeit HIV Medication Being Distributed in the United States

Gilead Sciences Statement on Positive Phase 3 AMBITION Study Findings for the Treatment of HIV-Associated Cryptococcal Meningitis

Gilead Sciences Response to Open Letter Regarding Access to AmBisome® (liposomal amphotericin B)

Gilead Statement on New England Journal of Medicine Publication of Positive Phase 3 ASCENT Study of Trodelvy in Metastatic Triple-Negative Breast Cancer

Gilead Sciences Statement on Phase 3 Veklury® (Remdesivir) Intravenous Study in High Risk Non-Hospitalized Patients with COVID-19

Gilead Announces Additional Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program

Gilead Announces Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program

Gilead Announces Plans for New Location in North Carolina’s Research Triangle Region Dedicated to Business Services

Gilead Sciences Statement on the Passing of the Honorable George P. Shultz, PhD

Gilead Sciences Statement on Recent Events in Washington, D.C.

Gilead Announces New Arm of HIV Women’s Prevention Study to Evaluate the Investigational Long-Acting HIV-1 Capsid Inhibitor Lenacapavir in Addition to Descovy for PrEP®

Gilead Sciences Statement on The World Health Organization’s Updated Veklury® (Remdesivir) COVID-19 Treatment Guidelines

Annual Reports

Careers

Careers at Gilead

Our Culture

Meet Our Employees

Inclusion and Diversity in Hiring

Compensation, Benefits and Wellbeing

Our Global Footprint

Early Career Opportunities

Internship Program

Postdoctoral Fellowships

Hiring Events

Talent Community Sign-up

Utility

Privacy Statements

Cookie Statement

Global Applicant Privacy Statement

Terms Of Use

Social Media Guidelines

Contact

Request Medicines Information

Report an Adverse Event

Partnership Request

Global Operations

North America

South America

Asia

Middle East

United Arab Emirates

Africa

Australia

Australia and New Zealand

Europe

Belgium and Luxembourg

Czech Republic & Slovakia

Poland & The Baltics